Secondary bladder cancer after permanent iodine-125 brachytherapy for prostate cancer

  • Hirayama Kidai
    Department of Urology, Showa University Graduate School of Medicine Department of Urology, Showa University School of Medicine
  • Fukagai Takashi
    Department of Urology, Showa University School of Medicine
  • Morita Masashi
    Department of Urology, Showa University School of Medicine
  • Oshinomi Kazuhiko
    Department of Urology, Showa University School of Medicine
  • Nishimura Kota
    Department of Urology, Showa University School of Medicine
  • Yamatoya Jin
    Department of Urology, Showa University School of Medicine
  • Nakagami Yoshihiro
    Department of Urology, Showa University School of Medicine
  • Toyofuku Kosuke
    Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
  • Niiya Akifumi
    Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
  • Kobayashi Rei
    Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
  • Nishimura Emi
    Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
  • Kato Masako
    Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
  • Morota Madoka
    Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
  • Ito Yoshinori
    Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine

抄録

Bladder cancer has been observed in patients after permanent iodine-125 brachytherapy (hereafter referred to as brachytherapy) for prostate cancer. We investigated secondary bladder cancer after brachytherapy. From January 2005 to March 2021, a total of 1,478 patients underwent brachytherapy for localized prostate cancer at Showa University Hospital and Showa University Koto Toyosu Hospital. A standardized incidence rate was calculated from the incidence of secondary bladder cancer after brachytherapy and compared with the national cancer registry general incidence data. The median follow-up was 4.7 years. Secondary bladder cancer occurred in 15 of 1478 patients (median age: 71 years). The incidence was 198 cases/100,000 persons/year. The incidence was 2.84 times higher than that of Japan’s national cancer registry. In addition, as a characteristic of secondary bladder cancer, the malignancy tended to be high regardless of the depth of invasion. The relative risk between cases with a secondary bladder cancer period until occurrence of >5 years and cases with a secondary bladder cancer period until occurrence of ≤5 years was 1.61 times (95% CI: 0.57-4.50), but the difference was not significant. In this study, we found that the incidence of bladder cancer was 2.84 times higher than that of the general population of Japan, suggesting that brachytherapy increases the risk of developing bladder cancer. To our knowledge, this study is the first to compare the incidence of brachytherapy and general bladder cancer in Japan. The results of this study suggest that although brachytherapy is effective for prostate cancer, attention should be paid to the early detection of bladder cancer because of the risk of secondary cancer development.

収録刊行物

参考文献 (15)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ